FDA Clears First Oral Device Treatment for Severe Sleep Apnea

The FDA cleared the first oral appliances for treating severe obstructive sleep apnea (OSA), Vivos Therapeutics announced on Wednesday.

The removable complete airway repositioning and/or expansion (CARE) line of oral appliances are an alternative treatment to continuous positive airway pressure (CPAP) or surgical neurostimulation implants for severe OSA, the company noted.

Supporting trial data involving 73 patients with severe OSA showed that 80% had an improvement of at least one OSA classification or a 50% or greater improvement in the Apnea Hypopnea Index with the devices. In addition, 97% of patients either improved or stayed the same. Average treatment time was 9.7 months.

“Make no mistake: this is a huge development on the landscape of treatments for OSA,” said David McCarty, MD, previously of Colorado Sleep Institute. “As the medical profession has gained a better understanding of the complex factors contributing to OSA, we now recognize that a critical component to this condition is the form and functionality of the oral vault.”

“This decision by the FDA could be life changing for patients who suffer from severe OSA and for whom other treatments have failed,” he added.

The agency had previously cleared the company’s daytime-nighttime (DNA) appliance for mild to moderate OSA in adults in January. The new clearance for severe OSA applies to the DNA appliance, the mandibular repositioning nighttime (mRNA) appliance, and the modified version of the mRNA (mmRNA). The oral appliances can be used along with positive airway pressure (PAP) and/or myofunctional therapy as needed.

Unlike other oral appliances on the market, the CARE appliances gradually reposition the hard and soft tissues that define the airway, thereby opening it up and optimizing its function and flow, Vivos explained.

No safety issues were observed, the company said, although some patients required aligners following treatment.

Elizabeth Short is a staff writer for MedPage Today. She often covers pulmonology and allergy & immunology. Follow

Vegan diet may slow aging

Vegan diets showed short-term benefits on epigenetic aging compared to omnivorous diets in healthy twins, with reduced epigenetic age metrics observed in the vegan group.

July 31, 2024

The health care industry is girding for Trump’s tariffs —and pushing hard for carveouts

President-elect Trump campaigned on imposing broad, steep tariffs to create more jobs in the U.S. and combat China. If enacted, these taxes would send the

November 21, 2024

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Ring Therapeutics, a gene therapy startup launched by Flagship Pioneering, has laid off just under 20% of its staff, or 19 employees, Flagship confirmed to

February 20, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.